Small caps can spend years being valued mainly on what might happen next. A mineral explorer talks about targets, a developer talks about future production, and a specialist technology business
BSF Enterprise Shares Jump 18% After US Patent Allowance for ETSYL Technology
BSF Enterprise Plc (LON: BSFA) shares jumped 18% after the US Patent and Trademark Office issued a Notice of Allowance covering key intellectual property behind its ETSYL® collagen technology.
Oxford Biomedica is now on M&A Alert
It has thus far refused four £9 offers from Swedish investment firm EQT, which is said to be looking at Oxford BioMedica plc (LON: OXB) again now that shares are
Avacta Reports Clinical Proof of Mechanism for AVA6103 in Phase 1 Trial
Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.
ImmuPharma Files International P140 Patent Application
ImmuPharma plc (AIM: IMM) has filed an international Patent Cooperation Treaty application covering its P140 precision medicine approach to autoimmune disease, including identifying and treating patients with the Type M immune
Avacta Appoints Mats Blom to Board as Audit Committee Chair
Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.
Physiomics Secures £205,000 of New Contracts as Four-Month Awards Top £750,000
Physiomics plc (AIM: PYC) has secured new contracts worth more than £205,000, extending a strong run of commercial wins for the mathematical modelling, data science and biostatistics specialist.
MedPal AI Strengthens Board as £28m Revenue Run Rate Drives Growth Incentive Package
MedPal AI plc (AIM: MPAL; FRA: Z1N) has appointed former eEnergy Group chief executive Harvey Sinclair as an independent non-executive director as the digital health group looks to strengthen its
Genflow Biosciences Trial Meets Primary Endpoint in Aged Beagles
Genflow Biosciences Ltd (LON: GENF) has reported that its SLAB clinical trial evaluating the company’s SIRT6 centenarian gene therapy in aged beagles has met its primary endpoint.
Novacyt Launch of IVDR-Certified Yourgene® Insight DPYD Assay
Novacyt (AIM: NCYT) has launched its IVDR-certified Yourgene® Insight DPYD assay across regulated European markets, expanding the company’s clinical genetics portfolio.
MedPal AI plc – From zero to £28 million annualised in ten months
MedPal AI plc (AIM: MPAL) has reported a sharp acceleration in trading, with its New Health GLP-1 weight-management business generating £1.83 million of revenue in August, an increase of more
Avacta pays £2.61m bond instalment as debt falls to £12m
Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.